Anne Marie Comeau to Neonatal Screening
This is a "connection" page, showing publications Anne Marie Comeau has written about Neonatal Screening.
Connection Strength
6.003
-
Sahai I, Eaton RB, Hale JE, Mulcahy EA, Comeau AM. Long-term follow-up to ensure quality care of individuals diagnosed with newborn screening conditions: early experience in New England. Genet Med. 2010 Dec; 12(12 Suppl):S220-7.
Score: 0.325
-
Hale JE, Bonilla FA, Pai SY, Gerstel-Thompson JL, Notarangelo LD, Eaton RB, Comeau AM. Identification of an infant with severe combined immunodeficiency by newborn screening. J Allergy Clin Immunol. 2010 Nov; 126(5):1073-4.
Score: 0.322
-
Gerstel-Thompson JL, Wilkey JF, Baptiste JC, Navas JS, Pai SY, Pass KA, Eaton RB, Comeau AM. High-throughput multiplexed T-cell-receptor excision circle quantitative PCR assay with internal controls for detection of severe combined immunodeficiency in population-based newborn screening. Clin Chem. 2010 Sep; 56(9):1466-74.
Score: 0.317
-
Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S255-61.
Score: 0.314
-
Comeau AM, Hale JE, Pai SY, Bonilla FA, Notarangelo LD, Pasternack MS, Meissner HC, Cooper ER, DeMaria A, Sahai I, Eaton RB. Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S273-81.
Score: 0.314
-
Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med. 2008 Feb 28; 358(9):973-4.
Score: 0.269
-
Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics. 2007 Feb; 119(2):e495-518.
Score: 0.249
-
Pass K, Green NS, Lorey F, Sherwin J, Comeau AM. Pilot programs in newborn screening. Ment Retard Dev Disabil Res Rev. 2006; 12(4):293-300.
Score: 0.231
-
Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. J Pediatr. 2005 Sep; 147(3 Suppl):S78-82.
Score: 0.226
-
Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005 Sep; 147(3 Suppl):S89-93.
Score: 0.226
-
Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005 Sep; 147(3 Suppl):S98-100.
Score: 0.226
-
Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004 Jun; 113(6):1573-81.
Score: 0.207
-
Comeau AM, Larson C, Eaton RB. Integration of new genetic diseases into statewide newborn screening: New England experience. Am J Med Genet C Semin Med Genet. 2004 Feb 15; 125C(1):35-41.
Score: 0.203
-
Parad RB, Comeau AM. Newborn screening for cystic fibrosis. Pediatr Ann. 2003 Aug; 32(8):528-35.
Score: 0.196
-
Ma KC, Hale JE, Grad YH, Alter G, Luzuriaga K, Eaton RB, Fischinger S, Kaur D, Brody R, Siddiqui SM, Leach D, Brown CM, Klevens RM, Madoff L, Comeau AM. Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens. Clin Infect Dis. 2022 08 24; 75(1):e105-e113.
Score: 0.183
-
Comeau AM, Eaton RB. Successes of newborn screening programs. Science. 2002 Jan 04; 295(5552):44-5.
Score: 0.175
-
Hale JE, Platt CD, Bonilla FA, Hay BN, Sullivan JL, Johnston AM, Pasternack MS, Hesterberg PE, Meissner HC, Cooper ER, Barmettler S, Farmer JR, Fisher D, Walter JE, Yang NJ, Sahai I, Eaton RB, DeMaria A, Notarangelo LD, Pai SY, Comeau AM. Ten Years of Newborn Screening for Severe Combined Immunodeficiency (SCID) in Massachusetts. J Allergy Clin Immunol Pract. 2021 05; 9(5):2060-2067.e2.
Score: 0.165
-
Comeau AM. Paradigm shifts in newborn screening? Genet Med. 2019 03; 21(3):534-535.
Score: 0.139
-
Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, Kwon JM, Lam WK, Ojodu J, Prosser LA, Tanksley S. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2017 01; 19(1):121-126.
Score: 0.120
-
Hinton CF, Homer CJ, Thompson AA, Williams A, Hassell KL, Feuchtbaum L, Berry SA, Comeau AM, Therrell BL, Brower A, Harris KB, Brown C, Monaco J, Ostrander RJ, Zuckerman AE, Kaye C, Dougherty D, Greene C, Green NS. A framework for assessing outcomes from newborn screening: on the road to measuring its promise. Mol Genet Metab. 2016 08; 118(4):221-9.
Score: 0.119
-
Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, Prosser LA, Ojodu J, Botkin JR, Kemper AR, Green NS. Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. Matern Child Health J. 2016 Mar; 20(3):693-700.
Score: 0.117
-
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, Baker M, Ballow M, Bartoshesky LE, Bonilla FA, Brokopp C, Brooks E, Caggana M, Celestin J, Church JA, Comeau AM, Connelly JA, Cowan MJ, Cunningham-Rundles C, Dasu T, Dave N, De La Morena MT, Duffner U, Fong CT, Forbes L, Freedenberg D, Gelfand EW, Hale JE, Hanson IC, Hay BN, Hu D, Infante A, Johnson D, Kapoor N, Kay DM, Kohn DB, Lee R, Lehman H, Lin Z, Lorey F, Abdel-Mageed A, Manning A, McGhee S, Moore TB, Naides SJ, Notarangelo LD, Orange JS, Pai SY, Porteus M, Rodriguez R, Romberg N, Routes J, Ruehle M, Rubenstein A, Saavedra-Matiz CA, Scott G, Scott PM, Secord E, Seroogy C, Shearer WT, Siegel S, Silvers SK, Stiehm ER, Sugerman RW, Sullivan JL, Tanksley S, Tierce ML, Verbsky J, Vogel B, Walker R, Walkovich K, Walter JE, Wasserman RL, Watson MS, Weinberg GA, Weiner LB, Wood H, Yates AB, Puck JM, Bonagura VR. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014 Aug 20; 312(7):729-38.
Score: 0.105
-
Comeau AM. Application of the polymerase chain reaction for the detection of HIV in specimens from newborn screening programs. Acta Paediatr Suppl. 1994 Aug; 400:29-30.
Score: 0.105
-
Botkin JR, Lewis MH, Watson MS, Swoboda KJ, Anderson R, Berry SA, Bonhomme N, Brosco JP, Comeau AM, Goldenberg A, Goldman E, Therrell B, Levy-Fisch J, Tarini B, Wilfond B. Parental permission for pilot newborn screening research: guidelines from the NBSTRN. Pediatrics. 2014 Feb; 133(2):e410-7.
Score: 0.101
-
Kemper AR, Green NS, Calonge N, Lam WK, Comeau AM, Goldenberg AJ, Ojodu J, Prosser LA, Tanksley S, Bocchini JA. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children. Genet Med. 2014 Feb; 16(2):183-7.
Score: 0.098
-
Kemper AR, Kus CA, Ostrander RJ, Comeau AM, Boyle CA, Dougherty D, Mann MY, Botkin JR, Green NS. A framework for key considerations regarding point-of-care screening of newborns. Genet Med. 2012 Dec; 14(12):951-4.
Score: 0.092
-
Comeau AM, Hsu HW, Schwerzler M, Mushinsky G, Grady GF. Detection of HIV in specimens from newborn screening programs. N Engl J Med. 1992 Jun 18; 326(25):1703.
Score: 0.091
-
Kemper AR, Knapp AA, Metterville DR, Comeau AM, Green NS, Perrin JM. Weighing the evidence for newborn screening for Hemoglobin H disease. J Pediatr. 2011 May; 158(5):780-3.
Score: 0.082
-
Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM. Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med. 2010 Sep; 12(9):539-43.
Score: 0.080
-
Perrin JM, Knapp AA, Browning MF, Comeau AM, Green NS, Lipstein EA, Metterville DR, Prosser L, Queally D, Kemper AR. An evidence development process for newborn screening. Genet Med. 2010 Mar; 12(3):131-4.
Score: 0.077
-
Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008 May; 121(5):e1108-14.
Score: 0.068
-
Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr. 2005 Sep; 147(3 Suppl):S69-72.
Score: 0.057
-
Day-Lewis ME, Berbert L, DeGrazia M, Yee C, Fried AJ, Nguyen AA, Hale JE, Counihan A, Comeau AM, Treffeisen ER, Reed MP, Platt CD, Chou J. Incidence and risk factors for CMV and EBV infection in infants with low T-cell receptor excision circles on newborn screen. Clin Immunol. 2025 Aug; 277:110510.
Score: 0.055
-
Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004 Oct 15; 53(RR-13):1-36.
Score: 0.053
-
Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, Prosser LA, Rose AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening. Pediatrics. 2023 08 01; 152(2).
Score: 0.049
-
Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, Prosser LA, Ros? AM, Comeau AM, Tanksley S, Powell CM, Kemper AR. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States. Genet Med. 2023 02; 25(2):100330.
Score: 0.047
-
Eaton RB, Comeau AM, Zytkovicz TH, Larson C. Newborn screening: new developments in a proven field. Clin Lab Sci. 2002; 15(4):239-44.
Score: 0.044
-
Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, Strauss AW, Comeau AM, Eaton RB, Grady GF. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001 Nov; 47(11):1945-55.
Score: 0.043
-
Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center. Genet Med. 2001 Nov-Dec; 3(6):411-5.
Score: 0.043
-
Delmonte OM, Biggs CM, Hayward A, Comeau AM, Kuehn HS, Rosenzweig SD, Notarangelo LD. First Case of X-Linked Moesin Deficiency Identified After Newborn Screening for SCID. J Clin Immunol. 2017 05; 37(4):336-338.
Score: 0.032
-
Punwani D, Gonzalez-Espinosa D, Comeau AM, Dutra A, Pak E, Puck J. Cellular calibrators to quantitate T-cell receptor excision circles (TRECs) in clinical samples. Mol Genet Metab. 2012 Nov; 107(3):586-91.
Score: 0.023
-
O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics. 2006 Sep; 118(3):1260-5.
Score: 0.015